<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="121042">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01941771</url>
  </required_header>
  <id_info>
    <org_study_id>EUDRACT nr. 2011-003564-72</org_study_id>
    <secondary_id>2011-003564-72</secondary_id>
    <nct_id>NCT01941771</nct_id>
  </id_info>
  <brief_title>Phase II Trial With Metronomic, Capecitabine Plus Oral Vinorelbine for Metastatic Breast Cancer</brief_title>
  <acronym>XeNa</acronym>
  <official_title>Randomized Phase II Trial of Capecitabine Plus Oral Vinorelbine Day 1 and 8 vs Metronomic Capecitabine Plus Oral Vinorelbine as Treatment of Metastatic Breast Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pierre Fabre Laboratories</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <authority>Denmark: Danish Health and Medicines Authority</authority>
    <authority>Denmark: Danish Dataprotection Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study hypothesis is that metronomic treatment is more efficient than standard treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose: In an open-label randomized phase II trial, patients with metastatic Human
      Epidermal Growth Factor Receptor 2-negative breast cancer with normal organ function sant
      WHO performance status &lt; 3 are randomized to receive either capecitabine (day 1-14) plus
      vinorelbine oral (day 1 and 8) or capecitabine (day 1-14) plus vinorelbine oral metronomic
      (3 days a week).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Primary endpoint is overall response rate i both arms.</measure>
    <time_frame>up to 60 month</time_frame>
    <safety_issue>No</safety_issue>
    <description>Response evaluation at 3rd and 6th cycle by resist criterias. The number of patients that respond to treatment in percent of the total number of patients treated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression.</measure>
    <time_frame>up to 60 month</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of days from start of treatment to progression of disease assessed up to 60 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival.</measure>
    <time_frame>up to 60 month</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of days from start of treatment to death assessed up to 60 months.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Toxicity</measure>
    <time_frame>Side effects of treatment</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Monitoring side effects of treatment assessed up to 60 months.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vinorelbine (Navelbine Oral) 60 mg/m2 day 1 and day 8 Plus Capecitabine (Xeloda) 1000 mg/m2 2 times daily day 1 to 14 in a 3 weekly schedule.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral Vinorelbine (Navelbine oral) 50 mg 3 times weekly, monday, wednesday and friday plus Capecitabine (Xeloda) 1000 mg/m2 2 times daily day 1-14 in a 3 weekly schedule.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arm B Vinorelbine (Navelbine oral) Capecitabine (Xeloda)</intervention_name>
    <description>Oral Vinorelbine (Navelbine oral) 50 mg 3 times weekly, monday, wednesday and friday plus Capecitabine (Xeloda) 1000 mg/m2 2 times daily day 1-14 in a 3 weekly schedule.</description>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Vinorelbine (Navelbine oral)</other_name>
    <other_name>Capecitabine (Xeloda)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arm A Vinorelbine (Navelbine oral) Capecitabine (Xeloda)</intervention_name>
    <description>Vinorelbine (Navelbine Oral) 60 mg/m2 day 1 and day 8 Plus Capecitabine (Xeloda) 1000 mg/m2 2 times daily day 1 to 14 in a 3 weekly schedule.</description>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>Other Names:</other_name>
    <other_name>Vinorelbine (Navelbine oral)</other_name>
    <other_name>Capecitabine (Xeloda)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Locally advanced or metastatic Human Epidermal Growth Factor Receptor2-Negative
             breast cancer

          -  WHO performance status &lt; 3

        Exclusion Criteria:

          -  Former treatment with Capecitabine or Vinorelbine

          -  Patients who have received more than one line of chemotherapy for metastatic disease

          -  Brain metastases

          -  Malabsorption syndrome

          -  Abnormal organ function

          -  pregnant or lactating women
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sven Tyge Langkjer, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University hospital of Aarhus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Oncology, Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <state>Aarhus C</state>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sven Tyge Langkjer, MD, ph.d.</last_name>
      <phone>+45 7846 9721</phone>
      <email>svenlang@rm.dk</email>
    </contact>
    <contact_backup>
      <last_name>Charlotte B Jensen, study nurse</last_name>
      <phone>+45 7846 4440</phone>
      <email>chajense@rm.dk</email>
    </contact_backup>
    <investigator>
      <last_name>Sven T Langkjer, MD, ph.d.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 12, 2013</lastchanged_date>
  <firstreceived_date>September 5, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Aarhus</investigator_affiliation>
    <investigator_full_name>Sven Langkjer</investigator_full_name>
    <investigator_title>consultant, MD, ph.d.</investigator_title>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>Metronomic chemotherapy</keyword>
  <keyword>Vinorelbine</keyword>
  <keyword>Navelbine</keyword>
  <keyword>Capecitabine</keyword>
  <keyword>Xeloda</keyword>
  <keyword>Antineoplastic Agents</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Antineoplastic Agents</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
